Sutro Biopharma Announces First Cohort Dosed in Phase 1 Trial of Stro-004

Sutro Biopharma has announced the dosing of the first cohort of patients in its phase 1 trial of Stro-004, a single homogeneous antibody drug conjugate targeting tissue factor for solid tumor treatment. The trial aims to evaluate the safety, pharmacokinetics, and pharmacodynamics of Stro-004. Sutro Biopharma is also developing STRO-002, an ADC directed against folate receptor-alpha for various cancers.